Back to top
more

McKesson (MCK)

(Delayed Data from NYSE)

$663.25 USD

663.25
2,172,445

-40.51 (-5.76%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $664.64 +1.39 (0.21%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

PerkinElmer's (PKI) Latest Launch to Boost Research Workflows

by Zacks Equity Research

PerkinElmer's (PKI) latest launch is expected to provide increased assay flexibility to researchers.

Zacks Equity Research

Reasons to Add Quest Diagnostics (DGX) Stock to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Quest Diagnostics (DGX) on its accelerated growth strategy and improvements in base volumes.

Zacks Equity Research

BD's (BDX) New FDA Approval to Improve Cervical Cancer Testing

by Zacks Equity Research

BD's (BDX) receipt of the latest FDA approval is likely to improve the detection and prevention of cervical cancer.

Zacks Equity Research

Are Investors Undervaluing AmerisourceBergen (ABC) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Insulet (PODD) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Insulet's (PODD) Q4 performance benefits from record quarterly U.S. and Total Omnipod new customer starts.

Zacks Equity Research

Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down

by Zacks Equity Research

Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.

Zacks Equity Research

Inogen (INGN) Q4 Earnings Beat Estimates, Revenues Lag

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

Zacks Equity Research

OPKO Health (OPK) Q4 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

Zacks Equity Research

Penumbra (PEN) Q4 Earnings Top Estimates, Sales Remain Robust

by Zacks Equity Research

Penumbra's (PEN) sales during the fourth quarter reflect continued demand for its products. The 2023 outlook is encouraging as EPS improves despite macro challenges.

Zacks Equity Research

Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.

Zacks Equity Research

DaVita (DVA) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Despite DaVita's (DVA) robust revenues in its Other segment, its overall Q4 performance was soft.

Zacks Equity Research

NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.

Zacks Equity Research

Merit Medical (MMSI) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Merit Medical (MMSI), in the fourth quarter, benefits from revenue growth in its Cardiovascular segment and the majority of product categories within its Cardiovascular unit.

Zacks Equity Research

Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.

Zacks Equity Research

Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y

by Zacks Equity Research

Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.

Zacks Equity Research

Fresenius Medical's (FMS) Q4 Earnings and Revenues Beat

by Zacks Equity Research

Fresenius Medical's (FMS) fourth-quarter revenues benefit from strong performance across all segments, especially in the North America and Asia-Pacific regions. However, rising costs hurt margins.

Zacks Equity Research

Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y

by Zacks Equity Research

Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.

Zacks Equity Research

Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip

by Zacks Equity Research

Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.

Zacks Equity Research

Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls

by Zacks Equity Research

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises

by Zacks Equity Research

Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.

Zacks Equity Research

Avanos (AVNS) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Avanos' (AVNS) fourth-quarter 2022 results reflect strength in both segments.

Zacks Equity Research

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.

Zacks Equity Research

Reasons to Retain Patterson Companies (PDCO) Stock Now

by Zacks Equity Research

Investors are optimistic about Patterson Companies' (PDCO) strong product line.

Zacks Equity Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH